You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The DXRX marketplace, planned for launch in the fourth quarter of 2020, will provide a way for pharmaceutical companies, diagnostic firms, and laboratories to collaborate.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
More than 70 percent of labs surveyed experienced supply chain interruptions, forcing them to validate three or more diagnostic testing methods.
The company, along with Softbank Investment Advisers, is offering a total of 11,500,000 shares of its common stock at $84 per share.
Sienna said that Unilabs, a commercial lab in Sweden, is evaluating its hTERT bladder cancer test for routine use.
The company said that by the end of June it would have made available more than 500,000 kits, which allow individuals to self-collect nasal samples at home.